|
|
| | 3-Indolizinebutanoic acid, 1-[4-[(1S)-1-[4-(2-methylpropyl)phenyl]butoxy]benzoyl]- Basic information |
| | 3-Indolizinebutanoic acid, 1-[4-[(1S)-1-[4-(2-methylpropyl)phenyl]butoxy]benzoyl]- Chemical Properties |
| density | 1.12±0.1 g/cm3(Predicted) | | pka | 4.75±0.10(Predicted) |
| | 3-Indolizinebutanoic acid, 1-[4-[(1S)-1-[4-(2-methylpropyl)phenyl]butoxy]benzoyl]- Usage And Synthesis |
| Uses | FR-146687 (FK 687) is a selective and orally active 5α-reductase inhibitor with IC50s of 1.7 nM and 4.6 nM for rat and human 5α-reductases, respectively. FR-146687 shows no inhibitory effects on other steroid oxidoreductases[1]. | | in vivo | FR-146687 (0.032-3.2 mg/kg; po; 2, 7, 14, or 21 days) dose-dependently reduces ventral prostate and seminal vesicle weight at doses above 0.1 mg/kg[1].
| Animal Model: | 4-week-old immature castrated male rats injected with Testosterone propionate (TP)[1] | | Dosage: | 0.032 mg/kg, 0.32 mg/kg, 3.2 mg/kg | | Administration: | po; 2, 7, 14, or 21 days | | Result: | Dose-dependently reduced ventral prostate and seminal vesicle weight at doses above 0.1 mg/kg.
|
| | References | [1] O Nakayama, et al. FR146687, a novel steroid 5 alpha-reductase inhibitor: in vitro and in vivo effects on prostates. Prostate. 1997 Jun 1;31(4):241-9. DOI:10.1002/(sici)1097-0045(19970601)31:4<241::aid-pros5>3.0.co;2-n |
| | 3-Indolizinebutanoic acid, 1-[4-[(1S)-1-[4-(2-methylpropyl)phenyl]butoxy]benzoyl]- Preparation Products And Raw materials |
|